Search Results
Your search for ,twO matches 12119 pages
Showing 4951 - 5000Taking Action Against Cancer: Celebrating 20 Years of World Cancer Day
February 4, 2020, will mark the 20th anniversary of World Cancer Day, an annual event meant to raise cancer awareness and encourage governments, oncology societies, nongovernmental organizations, businesses, and individuals to take action against the global impact of the disease. Formed in...
Oral CC-486 Maintenance Therapy Extends Survival in Older Patients With AML
Use of CC-486—an investigational oral form of azacitidine—as maintenance therapy significantly improved overall survival and relapse-free survival in older patients with newly diagnosed acute myeloid leukemia (AML) who were in remission following induction chemotherapy with or without consolidation ...
Olaparib for Previously Treated, Metastatic Castration-Resistant Prostate Cancer With DNA Repair Gene Aberrations
In the phase II TOPARP-B trial—reported by Joaquin Mateo, MD, in The Lancet Oncology—investigators found that olaparib showed good activity in men with metastatic castration-resistant prostate cancer and DNA damage response (DDR) gene aberrations who had received one or two prior taxane regimens....
ADMIRAL Trial: More Than Standard Chemotherapy Needed for FLT3-Mutant Advanced AML
The important ADMIRAL trial, reported by Perl et al in The New England Journal of Medicine1 and reviewed in this issue of The ASCO Post, shows the efficacy of a specific FLT3 inhibitor in patients with advanced acute myeloid leukemia (AML) and enhances the era of personalized medicine in leukemia. ...
First-Line Atezolizumab Plus Nab-paclitaxel in Advanced Triple-Negative Breast Cancer: Second Overall Survival Interim Analysis
As reported in The Lancet Oncology by Peter Schmid, MD, and colleagues, the prespecified second interim analysis of overall survival in the phase III IMpassion130 trial has shown no overall survival benefit with the addition of atezolizumab to nab-paclitaxel as first-line treatment of...
Expert Point of View: Debra A. Patt, MD, MPH, MBA, FASCO, and C. Kent Osborne, MD, FASCO
Debra A. Patt, MD, MPH, MBA, FASCO, Clinical Professor at Dell Medical School at The University of Texas at Austin and Executive Vice President of Public Policy and Strategy Initiatives for Texas Oncology, told attendees in a symposium highlights talk, “We all identify and follow some patients who ...
Fam-trastuzumab Deruxtecan-nxki for Previously Treated Unresectable or Metastatic HER2-Positive Breast Cancer
On December 20, 2019, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki was granted accelerated approval in the treatment of patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti–HER2-based regimens in the metastatic setting.1,2...
Breast Cancer Chemoprevention Effect Maintained Long After Stopping Anastrozole Therapy
For postmenopausal women at high risk for developing breast cancer—largely based on family history—anastrozole taken for 5 years maintained a preventive effect for at least an additional 7 years after stopping the drug in the IBIS-II trial, which included nearly 4,000 subjects. Women randomly...
A Deeper Understanding of the Miracle of the Human Body
Despite millennia of anatomic and biomedical search and discovery, there are parts and functions of the human body that remain a mystery. For years, medical students were taught that there are 78 organs in the human body. In February 2017, that number was revised, with the announcement of a new...
A Caregiver’s Tale of Struggle and Lingering Questions
The role of caregiver in the cancer scenario is complicated by various emotions and circumstances beyond the control of the caregiver and the person with cancer. Caregiver stress occurs when there isn’t the time to do all that’s asked or expected of one. Caregiver stress evolves into burnout when...
Seven Haircuts
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
FDA Grants Breakthrough Therapy Designation to Tucatinib in Combination Therapy for HER2-Positive Breast Cancer
Seattle Genetics recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tucatinib, in combination with trastuzumab and capecitabine, for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast...
Cancer No Longer Scares Me
Cancer was a disease I feared until 3 years ago, when I was diagnosed with gastric cancer. After receiving the diagnosis, I knew I didn’t have any time to indulge in fear; I had to take action if I was going to survive. In hindsight, symptoms of the cancer, including some fatigue and indigestion,...
Everolimus/Octreotide Shows Antitumor Activity in Recurrent Meningioma
According to the results from the small phase II CEVOREM trial, a targeted combination of the mTOR inhibitor everolimus and the somatostatin agonist octreotide showed antitumor activity in patients with recurrent meningioma not amenable to any type of surgery or radiotherapy. These findings were...
Radiation Oncologist Felix Y. Feng, MD, Strives for Balance Between Work and Family Life
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Felix Y. Feng, MD, Professor of Radiation Oncology, Urology, and Medicine; George and Judy Marcus Distinguished Professor; Vice Chair of Translational Research in the Department of Radiation...
Optimizing Metabolic Discoveries
Obesity is a leading cause of cancer, and researchers are working to learn more about the biology behind the body’s metabolism and the promotion of cancer growth. “While we know that physical activity and a balanced diet are generally healthy, we don’t yet have the data to make personalized...
Value-Based and Patient-Centered Cancer Care: Looking at Closing Gaps in Perspectives of Value
Value-based care in oncology—a concept that emphasizes quality over quantity—has evolved over the past 2 decades to become a guiding principle of both public and private payers. The concept was part of the Medicare Improvements for Patients and Providers Act (MIPPA) of 2008; informed elements of...
Two New Grants to Support Transformative Cancer Research
Two grants for research that could transform cancer therapies have been funded through an innovative partnership between the American Association for Cancer Research (AACR) and MPM Capital through its management of the UBS Oncology Impact Fund. This unique grant program allows investigators to...
2020 GI Cancers Symposium: Patient-Reported Outcomes From IMbrave150, BEACON CRC
Patient-reported outcomes from two large studies show that quality of life is maintained longer with newer drug combinations compared with standard-of-care treatments in patients with unresectable hepatocellular carcinoma and BRAF V600E–mutant metastatic colorectal cancer. The results, from...
2020 GI Cancers Symposium: Detecting GI Tumors Using a Cell-Free DNA Test
A blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal (GI) cancers could potentially help detect disease at earlier stages. This research will be presented by Brian M. Wolpin, MD, MPH, and colleagues at the 2020 Gastrointestinal Cancers...
Brentuximab Vedotin Plus Nivolumab in Hodgkin Lymphoma
The combination of brentuximab vedotin and nivolumab is making headway as first-line therapy for older adults with Hodgkin lymphoma and as salvage therapy for adults with relapsed or refractory classic Hodgkin lymphoma, according to separate studies presented at the 2019 Annual Meeting &...
Does Proton Pump Inhibitor Use Affect Cognition in Breast Cancer Survivors?
Proton pump inhibitors, which are sometimes recommended to ease stomach problems during cancer treatment, may have an unintended side effect: impairment of breast cancer survivors' memory and concentration. These findings were published by Madison et al in the Journal of Cancer Survivorship....
Mixed Results With Weekly Nab-paclitaxel, Denosumab in Primary Breast Cancer
A weekly schedule of nab-paclitaxel as part of neoadjuvant chemotherapy significantly improved pathologic complete response compared with nab-paclitaxel given 2 weeks out of every 3 weeks (2/3) in patients with primary breast cancer, with a greater magnitude of benefit in patients with...
Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes
We’ll start off this week by discussing results from the MEDALIST trial of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes. Then, we’ll move to a study that’s been covered a lot in the news: does the use of powder in the genital area increase a woman’s chance of ovarian...
Society for Integrative Oncology’s 16th International Conference
The Society for Integrative Oncology (SIO) hosted its 16th International Conference in New York City, October 19-21, 2019, in partnership with Memorial Sloan Kettering Cancer Center (MSK). The conference theme, “Advancing the Science and Art of Integrative Oncology,” focused on deepening the...
FDA Pipeline: Priority Reviews in Ovarian Cancer, Prostate Cancer, and NSCLC
This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to treatments for ovarian, prostate, and lung cancer; granted Orphan Drug designation to therapies for chemotherapy-induced thrombocytopenia and multiple myeloma; and granted Breakthrough Device designation to platforms...
Treatment Resistance and Novel Therapies in FGFR-Mutated Cholangiocarcinoma
A new study has shown how resistance to fibroblast growth factor receptor (FGFR) inhibitor treatment develops in patients with cholangiocarcinoma and suggests that adding another therapy at the time of disease progression might resensitize tumor cells to initial therapy. These findings were...
External-Beam Accelerated Partial-Breast Irradiation vs Whole-Breast Irradiation After Breast-Conserving Surgery in DCIS or Node-Negative Breast Cancer
As reported in The Lancet by Timothy J. Whelan, BM, BCh, and colleagues, the phase III noninferiority RAPID trial has shown that external-beam accelerated partial-breast irradiation is noninferior to whole-breast irradiation in reducing risk of local recurrence after breast-conserving surgery in...
Comparing Options for Ovarian Tissue Cryopreservation to Preserve Fertility in Pediatric Patients With Cancer
With the pediatric cancer survival rate exceeding 80%, “we can reasonably suspect that most of these children will survive more than 5 years from their diagnosis and then go on to puberty,” when they may have to deal with the consequences of cancer treatment, according to Rebecca Flyckt, MD,...
Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous NSCLC
In a Japanese phase III trial reported in the Journal of Clinical Oncology, Seto et al found that the addition of maintenance pemetrexed to bevacizumab did not significantly improve overall survival in patients with previously untreated, advanced nonsquamous non–small cell lung cancer (NSCLC)...
Selected Abstracts on Novel Therapies for Chronic Myeloid Leukemia
To complement The ASCO Post’s comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens for chronic myeloid leukemia (CML). For full details of...
Blinatumomab Outperforms Chemotherapy as Post-Reinduction Consolidation Therapy in Younger Patients With B-Cell ALL
Blinatumomab was superior to standard chemotherapy in children, adolescents, and young adults at the first relapse of B-cell acute lymphoblastic leukemia (ALL) as post-reinduction consolidation therapy prior to hematopoietic stem cell transplant (HSCT), according to the results of a late-breaking...
Cancer Survivors Face Substantial Medical Financial Hardship
Although advances in cancer treatments have led to huge increases in the number of survivors in the United States—more than 16.9 million in 2019—many of those survivors, particularly those aged 18 to 64, face substantial medical financial hardship due to their diagnosis and treatment, necessitating ...
Selected Abstracts on New Therapies for Newly Diagnosed Multiple Myeloma
To complement The ASCO Post’s comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens including the monoclonal antibody daratumumab in combination ...
Activity of Belantamab Mafodotin in Patients With Heavily Pretreated Relapsed or Refractory Multiple Myeloma
In the phase II DREAMM-2 trial reported in The Lancet Oncology, Sagar Lonial, MD, and colleagues found that the antibody-drug conjugate belantamab mafodotin was active in patients with heavily pretreated relapsed or refractory multiple myeloma. The agent is a conjugate of an anti–B-cell maturation...
ADMIRAL Trial: Gilteritinib Improves Overall Survival in Relapsed or Refractory FLT3-Mutated AML
As reported in The New England Journal of Medicine by Alexander E. Perl, MD, of Abramson Cancer Center, University of Pennsylvania, and colleagues, the phase III ADMIRAL trial showed improved overall survival with the oral FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib vs salvage...
Activity of Ruxolitinib in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia
In a phase II study reported in the Journal of Clinical Oncology, Dao et al found that the JAK1/2 inhibitor ruxolitinib was active in patients with chronic neutrophilic leukemia (CNL), with less activity observed in those with atypical chronic myeloid leukemia (CML) and greater activity observed...
Transplantation Specialist Karen Ballen, MD, Treasures Long-Term Connections With Her Patients
Karen Ballen, MD, an international expert in stem cell transplantation, particularly for patients who have a difficult time finding a donor, was born and reared in the Bronx in a family that encouraged academic and professional pursuits. “My grandfather was an old-fashioned pediatrician who made...
Does Statin Use Increase Overall Survival in Patients With Colorectal Cancer?
About 40 million adults in the United States take a statin to lower their cholesterol and reduce the risk for heart disease—but they may also be getting an added anticancer benefit, a growing body of evidence suggests. According to research presented at the American Heart Association’s Scientific...
Prevalence of Alcohol Use Among Patients With Cancer and Survivors
New research published by Nina N. Sanford, MD, and colleagues in JNCCN—Journal of the National Comprehensive Cancer Network has found most cancer survivors reported that they are current alcohol drinkers, with a subset of those survivors self-reporting excessive drinking behaviors. “We recommend...
Noninferiority of Four vs Six Cycles of CHOP for Patients With Favorable Prognosis B-Cell Lymphoma: FLYER Trial
As reported in The Lancet by Viola Poeschel, MD, and colleagues, the phase III FLYER trial has shown noninferiority of progression-free survival with four vs six cycles of cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) in combination with six doses of rituximab in patients with...
Many Pelvic Examinations and Papanicolaou Tests Performed on Young Women May Be Unnecessary
Pelvic examinations and cervical cancer screenings are no longer recommended for most females under age 21 during routine health visits, but a new study has found that millions of young women are undergoing the tests, which can lead to false-positive testing, overtreatment, anxiety, and needless...
Olaparib for Previously Treated, Metastatic Castration-Resistant Prostate Cancer With DNA Repair Gene Aberrations
In the phase II TOPARP-B trial—reported by Mateo et al in The Lancet Oncology—investigators found that olaparib showed activity in men with metastatic castration-resistant prostate cancer and DNA damage response (DDR) gene aberrations who had received one or two prior taxane regimens. Study...
T-DM1 Shows Activity in HER2-Amplified Salivary Gland Cancer in Small Patient Sample of NCI-MATCH
The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) showed activity in HER2-amplified salivary gland tumors, according to data published by Jhaveri et al in Annals of Oncology. The publication is for ‘Arm Q,’ which is one of nearly 40 single-arm phase II treatments in the NCI-Molecular...
Is Pembrolizumab Active in Pediatric Patients With PD-L1–Positive Advanced Solid Tumors or Lymphoma?
Interim analysis of the phase I/II KEYNOTE-051 trial, reported in The Lancet Oncology by Geoerger et al, indicated minimal activity of pembrolizumab in pediatric patients with programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed, or refractory solid tumors; however, activity was...
One Cycle of Bleomycin/Etoposide/Cisplatin May Be as Effective as Two for Patients With Testicular Cancer
Testicular cancer recurrence may be prevented by giving men one cycle of chemotherapy instead of the two cycles used as standard. Lowering the overall exposure to chemotherapy also reduced side effects. These findings were published by Cullen et al in European Urology. Testicular cancer is the most ...
Neoadjuvant vs Concurrent ADT With Dose-Escalated Radiotherapy for Localized Prostate Cancer
In a two-institute phase III trial reported in the Journal of Clinical Oncology, Malone et al found no difference in biochemical relapse–free survival with androgen-deprivation therapy (ADT) initiated prior to or concurrently with dose-escalated external-beam radiotherapy in patients with localized ...
Long-Term Results of IBIS-II: Anastrozole for Breast Cancer Prevention
As reported by Jack Cuzick, PhD, and colleagues in The Lancet, blinded follow-up of the IBIS-II trial has shown the continued benefit of anastrozole vs placebo in preventing breast cancer in high-risk postmenopausal women during the 5-year posttreatment period. For the international double-blind...
Osimertinib in Patients With NSCLC Harboring Uncommon EGFR Mutations
In a Korean phase II study reported in the Journal of Clinical Oncology, Myung-Ju Ahn, MD, PhD, and colleagues found that osimertinib was active in patients with metastatic or recurrent non–small cell lung cancer (NSCLC) with uncommon EGFR mutations. Study Details In the multicenter study, 36...
Asciminib for Patients With CML After Failure of ABL Kinase Inhibitor Treatment
In a phase I trial reported in The New England Journal of Medicine, Hughes et al found that asciminib, an oral BCR-ABL1 inhibitor with a mechanism of action different from available ABL1 tyrosine kinase inhibitors, was active in patients with chronic myeloid leukemia (CML) after failure of ABL...
